Cytokinesis-blocked micronucleus assay and cancer risk assessment

被引:49
作者
El-Zein, Randa [1 ]
Vral, Anne [2 ]
Etzel, Carol J. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Div Canc Prevent & Populat Sci, Unit 1340, Houston, TX 77030 USA
[2] Univ Ghent, Univ Hosp, Dept Basic Med Sci, B-9000 Ghent, Belgium
关键词
PERIPHERAL-BLOOD LYMPHOCYTES; STRAND BREAK REPAIR; SISTER-CHROMATID EXCHANGES; END-JOINING GENES; MUTAGEN SENSITIVITY; CHROMOSOMAL RADIOSENSITIVITY; LUNG-CANCER; BRCA1; MUTATION; DNA-REPAIR; FOLIC-ACID;
D O I
10.1093/mutage/geq071
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cancer risk assessment is a multidisciplinary process that goes beyond the scope of classical epidemiology to include the biological evaluation of individual differences to carcinogenic exposures. The inclusion of genetic biomarkers such as mutagen sensitivity or cytokinesis-blocked micronucleus (CBMN) assay end points into risk assessment models allows for a more comprehensive determination of cancer risk that includes known demographic (age and gender), lifestyle exposures (smoking and alcohol) and occupational or environmental exposures. The CBMN assay generates multiple correlated end points that, after applying data reduction methods, could be combined into a summary measure that incorporates information from each individual variable into a single (or possible multiple, uncorrelated) measure of risk. In this article, we highlight the use of the CBMN assay in radiosensitivity assessment. In addition, we demonstrate the potential use of the combined summary measures in cancer risk assessment as a result of chronic exposure to tobacco carcinogens. The simplicity, rapidity and sensitivity of the CBMN assay not only make it a valuable tool for screening but also the multiple end points simultaneously generated lead to a better understanding of the underlying mechanisms involved in the carcinogenic process that could in turn substantially improve risk predictions.
引用
收藏
页码:101 / 106
页数:6
相关论文
共 100 条
[1]  
ADHVARYU SG, 1988, CANCER-AM CANCER SOC, V61, P1867, DOI 10.1002/1097-0142(19880501)61:9<1867::AID-CNCR2820610924>3.0.CO
[2]  
2-F
[3]   INCREASED FREQUENCY OF SISTER CHROMATID EXCHANGES IN LYMPHOCYTES OF BREAST-CANCER PATIENTS [J].
ADHVARYU, SG ;
RAWAL, UM ;
PATEL, JV ;
PATEL, DD ;
BALAR, DB .
INTERNATIONAL JOURNAL OF CANCER, 1988, 41 (03) :394-398
[4]   Chromosomal radio sensitivity of breast cancer with a CHEK2 mutation [J].
Baeyens, A ;
Claes, K ;
Willems, P ;
De Ruyck, K ;
Thierens, H ;
Vral, A .
CANCER GENETICS AND CYTOGENETICS, 2005, 163 (02) :106-112
[5]   Effects of estradiol and progesterone on the variability of the micronucleus assay [J].
Baeyens, A ;
Vandersickel, V ;
Thierens, H ;
De Ridder, L ;
Vral, A .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2005, 578 (1-2) :308-316
[6]  
Baeyens A, 2005, ONCOL REP, V13, P347
[7]   Chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers [J].
Baeyens, A ;
Thierens, H ;
Claes, K ;
Poppe, B ;
De Ridder, L ;
Vral, A .
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2004, 80 (10) :745-756
[8]   Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition [J].
Baeyens, A ;
Thierens, H ;
Claes, K ;
Poppe, B ;
Messiaen, L ;
De Ridder, L ;
Vral, A .
BRITISH JOURNAL OF CANCER, 2002, 87 (12) :1379-1385
[9]   Radiosensitivity of peripheral blood lymphocytes obtained from patients with cancers of the breast, head and neck or cervix as determined with a micronucleus assay [J].
Ban, S ;
Konomi, C ;
Iwakawa, M ;
Yamada, S ;
Ohno, T ;
Tsuji, H ;
Noda, S ;
Matui, Y ;
Harada, Y ;
Cologne, JB ;
Imai, T .
JOURNAL OF RADIATION RESEARCH, 2004, 45 (04) :535-541
[10]  
Baria K, 2001, CANCER RES, V61, P5948